Leadership from Insilico Medicine is set to attend the 42nd Annual JP Morgan Healthcare Conference in San Francisco from January 8-11, 2024.
Leadership from Insilico Medicine, a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, is set to attend the 42nd Annual JP Morgan Healthcare Conference in San Francisco from January 8-11, 2024. The event serves as a premier platform for industry leaders, emerging companies, and investors in the healthcare sector.
Insilico’s representatives at the conference include Founder and CEO, Alex Zhavoronkov, PhD; Chief Business Officer, Michelle Chen, PhD; Global Head of AI Platforms and President of Insilico Medicine Canada, Petrina Kamya, PhD; Chief Medical Officer, Sujata Rao, MD; Head of Business Development, APAC, Jue Wang, PhD; and Associate Director of Business Development, Sean Cullen, PhD.
At the forefront of the generative AI revolution in drug discovery, Insilico’s platform integrates generative AI with an autonomous AI-powered robotics lab. The company has successfully generated a pipeline of over 30 assets across 29 targets for various diseases, including cancer, fibrosis, and inflammatory bowel disease (IBD). Notably, five of these assets have progressed into clinical trials.
Insilico’s achievements include having the first AI-discovered and AI-designed drug for idiopathic pulmonary fibrosis (IPF) in Phase II trials. The company has also entered into partnerships with major pharmaceutical companies like Sanofi and Exelixis to advance AI assets in cancer and other therapeutic areas. Platform licensing agreements with industry giants such as Novo Nordisk and Janssen further underscore Insilico’s commitment to driving new discoveries in liver fibrosis and neuroscience.
In December, Insilico announced a groundbreaking development, with its AI-designed treatment for IBD entering clinical trials. This marks the fifth AI-designed drug from Insilico to reach this stage, showcasing the platform’s potential in addressing diseases with limited therapeutic options.
Earlier in 2023, Insilico presented data at major cancer conferences, including the European Society for Medical Oncology (ESMO), the Society of Immunotherapy of Cancer (SITC), and the San Antonio Breast Cancer Symposium (SABCS). The company’s cancer-focused drugs in development include a CDK12/13 inhibitor for triple-negative breast cancer, an ENPP1 immunotherapy for multiple tumor types, and a KAT6 inhibitor for advanced ER+/HER2- breast cancer – the most prevalent subtype.
Insilico’s commitment to innovation is further exemplified by substantial updates to its end-to-end platform, featuring enhanced functionality such as chat capability. Additionally, the company celebrated the Grand Opening of its AI R&D center in Montreal in November, solidifying its position as a leader in AI-driven drug discovery.
To date, Insilico Medicine has secured over $400 million in funding from prominent biotech and tech investors, reflecting the industry’s confidence in the potential of AI to revolutionize drug development. The company’s participation in the J.P. Morgan Healthcare Conference signals its ongoing dedication to advancing groundbreaking solutions in healthcare through the power of artificial intelligence.